Related Experiment Video
Updated: Oct 11, 2025
07:44
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
Published on: May 12, 2023
1.3K
Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray
Jovin J Y Choo1, Christopher L D McMillan1, Germain J P Fernando1,2
1Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Vaccines
|November 27, 2021
Summary
Human serum albumin (HSA) stabilizes dry-coated vaccines on high-density microarray patches (HD-MAPs), ensuring full potency retention after six months of storage. This advance supports stable vaccine delivery via novel microneedle patch technology.
Area of Science:
- Vaccinology
- Biomaterials Science
- Immunology
Background:
- Traditional vaccine delivery methods face challenges with stability and administration.
- High-density microarray patches (HD-MAPs) offer an alternative delivery system with potential benefits.
- Ensuring vaccine stability in a dry-coated state on microneedle patches is crucial for efficacy.
Purpose of the Study:
- To identify pharmaceutical excipients that stabilize a live chimeric virus vaccine candidate (BinJ/DENV2-prME) during drying and storage on HD-MAPs.
- To evaluate the impact of storage conditions and wear time on vaccine stability and immunogenicity.
- To assess the long-term recovery and potency of the vaccine formulation.
Main Methods:
- Screening of pharmaceutical excipients for vaccine stabilization on HD-MAPs.
- Dry coating of a live chimeric virus vaccine (BinJ/DENV2-prME) onto HD-MAPs.
- Storage of coated HD-MAPs at 4°C and assessment of vaccine potency via antibody responses in mice.
- Evaluation of vaccine deposition and immunological outcomes based on HD-MAP wear time.
Main Results:
- Human serum albumin (HSA) was identified as the lead stabilizing excipient.
- Vaccine-coated HD-MAPs stored at 4°C for one month showed complete retention of vaccine potency.
- HD-MAP wear time did not affect vaccine deposition or immunological outcomes.
- The HSA-containing formulation maintained approximately 100% recovery after 6 months of storage at 4°C.
Conclusions:
- HSA significantly enhances the stability of dry-coated vaccines on HD-MAPs.
- HD-MAPs demonstrate a promising platform for stable, long-term storage of vaccines.
- This formulation strategy ensures vaccine potency and effective delivery via microneedle patches.
